Results 111 to 120 of about 61,613 (221)
Molecular Oncology, Volume 20, Issue 11, Page 2569-2583, November 2026.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Advanced Materials for Biologics Delivery to Brain Tumors
Advanced Materials, Volume 38, Issue 61, 2 November 2026.Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng +4 more
wiley +1 more source
, 2020 Aims. We here investigated whether the combination of simvastatin and irinotecan could induce the synergistic effect on colon cancer cells with or without resistance to irinotecan. Methods. We investigated cell proliferation assay and assessed cell death
Hyun Joo Jang +9 more
core
Supplementary Material for: Irinotecan-Induced Dysarthria
, 2017 Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 46-year-old patient with metastatic rectal carcinoma who received second ...
van der Vliet H.J. (4131472) +4 more
core +1 more source
Analysis &Sensing, Volume 6, Issue 6, November 2026.For aptamers to be adapated into function electrochemical sensors, the binding‐induced conformational change has to occur within a short distance away from the electrode surface. Aptamers that undergo structural rearrangement upon ligand binding have increasingly been translated into sensing platforms such as electrochemical aptamer‐based biosensors ...
Minh‐Dat Nguyen +6 more
wiley +1 more source
Background: Irinotecan is a topoisomerase I inhibitor used for the treatment of various cancers, such as gastrointestinal, pancreatic, pulmonary, ovarian, and cervical cancers.
Radu Serescu +7 more
core +1 more source
Cancer Medicine, Volume 15, Issue 11, November 2026.ABSTRACT Background Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in cancer patients. The AVERT trial showed apixaban thromboprophylaxis reduced VTE in intermediate‐to‐high‐risk patients initiating chemotherapy. However, the efficacy and safety of apixaban according to baseline chemotherapy class remain incompletely ...
Nadia Linxi Feng +10 more
wiley +1 more source
CPT: Pharmacometrics & Systems PharmacologyPeritoneal metastases (PM) are common in patients with colorectal cancer. Patients with PM have a poor prognosis, and for those who are not eligible for cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC ...
Pascale C. S. Rietveld +9 more
doaj +1 more source
Frontiers in OncologyIntroductionThe aim of this study was to provide a review of the clinical evidence for use of ramucirumab (RAM) plus folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan (FOLFIRI) or irinotecan as second-line treatment in gastroesophageal ...
Haeseong Park +8 more
doaj +1 more source
Cancer Medicine, Volume 15, Issue 11, November 2026.ABSTRACT Relapse occurs in 10%–20% of children with hepatoblastoma and is associated with inferior outcomes, yet standardized management remains limited. Defining risk factors and relapse patterns, as well as the role of surgery, particularly transplantation, is critical to optimizing survival. A retrospective review was performed of patients aged 0–18
Marissa Ray +14 more
wiley +1 more source